Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy — COLOWISE  

Colorectal Cancer Clinical Trial

Official title: Real-time Computer-Aided Detection of Colonic Adenomas With NEC WISE VISION® Endoscopy: Prospective, Randomized Clinical Performance Evaluation

Status Recruiting

Clinical Trial Summary

This is a prospective, multicenter, randomized study to evaluate the clinical performance of a novel CADe device, WISE VISION® Endoscopy System, in patients undergoing high-definition white light (HDWL) colonoscopy for screening or surveillance of colorectal Cancer (CRC). Eligible subjects who meet the study inclusion/exclusion criteria will be randomized in a 1:1 ratio to undergo colonoscopy : - Experimental: CADe colonoscopy procedure with WISE VISION® Endoscopy (CADe Group) - Control: Standard Colonoscopy without CADe (Standard Colonoscopy Group)

Clinical Trial Description

This study aims to evaluate whether NEC WISE VISION® Endoscopy enhances the ability to detect mucosal lesions when compared with the current standard-of-care procedure (high-definition white light [HDWL] colonoscopy). The CADe device, Wise VISION® Endoscopy, contains an artificial intelligence/machine learning (AI/ML) advanced algorithm to aid the endoscopists in detection of colonic lesions. This study plans to enrol 830 subjects aged ≥ 45 years and < 75 years, who are scheduled for screening or surveillance colonoscopy. After review of the inclusion and exclusion criteria, eligible subjects will be randomized in a 1:1 ratio to receive either computer-aided colonoscopy (CADe Group) or standard colonoscopy without CADe (Standard Colonoscopy Group). All adenomas, that are identified during the colonoscopies, will be removed and biopsied as per standard clinical practice to assess adenoma miss rate, polyp miss rate, adenomas per colonoscopy and other endpoints. ;

Related Conditions & MeSH terms

• Adenoma
• Adenoma Colon
• Colonic Polyps
• Colorectal Cancer
• Polyp of Colon

• NCT number: NCT05611151
• Study type: Interventional
• Source: NEC Corporation
• Contact: Monica Tocchi, MD, PhD
• Phone: +1 646 933 1025
• Email: m.tocchi@meditrial.net
• Status: Recruiting
• Phase: N/A
• Start date: April 30, 2023
• Completion date: January 30, 2025